Copyright © 2000 by the European Society of Cardiology.
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial
a Karolinska Institutet, Stockholm, Sweden
b University of Alberta, Edmonton, Canada
c University of Hull, U.K.
d University of Adelaide, Adelaide, Australia
e University of California, San Francisco, U.S.A.
f Columbia University, New York, U.S.A.
g Imperial College School of Medicine, University of London, U.K.
revised June 20, 2000; accepted June 21, 2000
Abstract
Aims An analysis was designed to determine whether chronic heart failure patients at high cardiovascular risk benefited to the same extent from high-dose lisinopril as the whole ATLAS population.
Methods and Results A retrospective analysis was performed on high-risk heart failure patients in the Assessment of Treatment with Lisinopril And Survival (ATLAS) trial (total number of patients 3164) comparing highdose (32·5–35mg.day–1) vs low-dose (2·5–5mg.day–1) lisinopril for a median of 46 months. These high-risk patients included those with hypotension, hyponatraemia, compromised renal function, the elderly and patients with diabetes mellitus at baseline. In the whole study population, high-dose lisinopril led to a trend in risk reduction of all-cause mortality (primary end-point P=0·128) and a significant risk reduction in all-cause mortality plus hospitalization (principal secondary end-point P=0·002). Subgroup analyses were performed for these end-points. There were no consistent interactions between age, baseline sodium, creatinine or potassium values, and treatment effect. Diabetics showed a beneficial response to high-dose therapy that was at least as good as that in non-diabetics. The underlying higher morbidity/mortality rates in diabetics mean that high-dose lisinopril has potential for a larger absolute clinical impact in these patients.
Conclusion Long-term high-dose lisinopril was as effective and well-tolerated in high-risk patients, including those with diabetes mellitus, as for the ATLAS study population as a whole.
Key Words: Heart failure, ACE inhibitor, mortality, hospitalization, lisinopril, diabetes mellitus
f1 Correspondence: Lars Rydén MD, Professor of Cardiology, Department of Cardiology, Karolinska Sjukhuset, S-171 76 Stockholm, Sweden.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. R. MacDonald, M. C. Petrie, N. M. Hawkins, J. R. Petrie, M. Fisher, R. McKelvie, D. Aguilar, H. Krum, and J. J.V. McMurray Diabetes, left ventricular systolic dysfunction, and chronic heart failure Eur. Heart J., May 2, 2008; 29(10): 1224 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74. [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Frazier, K. P. Alexander, L. K. Newby, S. Anderson, E. Iverson, M. Packer, J. Cohn, S. Goldstein, and P. S. Douglas Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction: A Pooled Analysis of 5 Randomized Control Trials J. Am. Coll. Cardiol., April 3, 2007; 49(13): 1450 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. C. Hoppe, N. Freemantle, J. G.F. Cleland, M. Marijianowski, and E. Erdmann Effect of Cardiac Resynchronization on Morbidity and Mortality of Diabetic Patients With Severe Heart Failure Diabetes Care, March 1, 2007; 30(3): 722 - 724. [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J., January 1, 2007; 28(1): 88 - 136. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Volpe, G. Tocci, and E. Pagannone Fewer Mega-Trials and More Clinically Oriented Studies in Hypertension Research? The Case of Blocking the Renin-Angiotensin-Aldosterone System. J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S36 - S43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. de Groote, N. Lamblin, F. Mouquet, D. Plichon, E. McFadden, E. Van Belle, and C. Bauters Impact of diabetes mellitus on long-term survival in patients with congestive heart failure Eur. Heart J., April 2, 2004; 25(8): 656 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Vaur, P. Gueret, M. Lievre, S. Chabaud, and P. Passa Development of Congestive Heart Failure in Type 2 Diabetic Patients With Microalbuminuria or Proteinuria: Observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study Diabetes Care, March 1, 2003; 26(3): 855 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P A Poole-Wilson, B F Uretsky, K Thygesen, J G F Cleland, B M Massie, and L Ryden Mode of death in heart failure: findings from the ATLAS trial Heart, January 1, 2003; 89(1): 42 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bartnik, K. Malmberg, and L. Ryden Diabetes and the heart: compromised myocardial function -- a common challenge Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B33 - B41. [Abstract] [PDF]
|
|
|
|
|
|
K. Swedberg Is more better? About dose levels of ACE inhibitors in chronic heart failure Eur. Heart J., December 1, 2000; 21(23): 1902 - 1903. [PDF]
|
|